...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical drug investigation >Consumption and distribution of propofol in anaesthesia and intensive care use in finland
【24h】

Consumption and distribution of propofol in anaesthesia and intensive care use in finland

机译：芬兰麻醉中异丙酚的消费和分布以及重症监护室的使用

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Propofol is approved both for anaesthesia and sedation during intensive care.Serious adverse reactions with propofol have recently been re ported, but patient exposure to the drug is unknown.Objective: To investigate the consumption of propofol in Finnish hospitals and to develop a denominator to estimate patient exposure.Methods: The consumption of propofol was investigated using the drug consumption database for 1990-2001.Distribution between anaesthesia and intensive care use in Finnish hospitals was investigated by a survey covering the period 2000-2001.We based the estimate of patient exposure on doses commonly described in the literature on propofol use in different indications.Results: Total consumption of propofol increased more than 4-fold from 1990-2001.Most of the propofol consumed was the 10 mg/mL strength.In 2001, one-third of the total sales consisted of the 20 mg/mL strength.In 2000 and 2001, a little more than half of the total consumption of propofol was used for sedation in intensive care.Conclusion: The use of propofol is increasing in Finland.Half of the propofol was used in anaesthesia units and half in intensive care units.We propose the following defined daily doses: 175mg for anaesthesia induction; 750 mg/patient-hour for anaesthesia maintenance; and 4200 mg/patient-day for sedation in intensive care.
机译：背景：丙泊酚被批准用于重症监护期间的麻醉和镇静。最近报告了丙泊酚的严重不良反应，但患者接触该药物的情况尚不清楚。目的：调查芬兰医院丙泊酚的消费量并建立分母方法：使用1990-2001年的药物消费数据库调查丙泊酚的消费量，通过覆盖2000-2001年的调查调查芬兰医院麻醉和重症监护使用之间的分布。结果：从1990年至2001年，丙泊酚的总消耗量增加了4倍以上;丙泊酚的最大消耗量是10 mg / mL强度.2001年，丙泊酚的摄入量为10 mg / mL。总销售额的三分之二是20 mg / mL的浓度。在2000年和2001年，丙泊酚的总消费量略高于一半结论：在芬兰，丙泊酚的使用正在增加。一半的异丙酚用于麻醉病房，一半用于重症监护病房。我们建议以下规定的每日剂量：175mg用于麻醉诱导; 750 mg /患者·小时，用于维持麻醉;重症监护中使用镇静剂和每天4200 mg。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号